MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.7248 -0.0410 (-5.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
31 32 Next >
News headline image
Why Is Lexaria Bioscience (LEXX) Stock Down 27% Today? ↗
Lexaria Bioscience (LEXX) stock is falling on Tuesday after the company revealed details about its public share offering. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why ClearOne Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket ↗
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) gained 74.2% to $0.2701 in pre-market trading after gaining around 7% on Monday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! 
Via InvestorPlace
News headline image
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
Via ACCESSWIRE
News headline image
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Dosing Completed on Human Clinical Nicotine Study
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Dosing Completed on Human Clinical Nicotine Study
Via Investor Brand Network
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Four New Patents Added to the Company’s Growing Patent Portfolio
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX), Featured in Recent Research Report by Zacks SCR
Via Investor Brand Network
Topics Bonds
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards CRO Contract for Upcoming Hypertension Study
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expanding Portfolio with Four New Patents
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria is Receiving Four New Patents
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes the Licensed Use of its DehydraTECH(TM) Technology to Complement its Royalty Earnings and Realize Revenue in Advance of Royalties
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Positive Results in First Diabetes Study
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patented DehydraTECH(TM) Technology Platform
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Foundation for Improving Effectiveness of Lipophilic Drugs, APIs
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Foundation for Improving Effectiveness of Lipophilic Drugs, APIs
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Confident that 2023 will be Lexaria’s Best Year Ever
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Drug Delivery Technology Demonstrates Growing List of Potential Applications as Evidenced Through Numerous R&D Programs
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Tracking Proprietary Path to Drug Delivery Innovation and Commercialization on Robust R&D Programs
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Additional Findings From Human Clinical Study, Demonstrating DehydraTECH(TM)-CBD Effects on Hypertension
Via Investor Brand Network
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story